World’s first anti-depression nasal spray receives FDA approval

World’s first anti-depression nasal spray receives FDA approval

/ 07:13 AM February 04, 2025

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato.

The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent version of ketamine.

READ: AI can diagnose depression better than doctors

Article continues after this advertisement

Spravato doesn’t work for everyone, but it can be life-changing to some. 

FEATURED STORIES

How does the anti-depression nasal spray work?

Johns Hopkins Medicine says Spravato boosts serotonin, norepinephrine and dopamine levels, similar to regular antidepressants.

However, this new medicine increases glutamate, the most abundant chemical messenger in the brain.

Article continues after this advertisement

As a result, the anti-depression nasal spray has a greater impact on more brain cells than conventional antidepressants.

Article continues after this advertisement

It’s available as a monotherapy, but Johns Hopkins says patients must take it with a conventional antidepressant. 

Article continues after this advertisement

Esketamine should only provide rapid relief from depression symptoms until other medications take effect.  

The first dose can distort a patient’s perception. That’s why they take the initial dose in a clinic, and doctors must observe them for two hours.

Article continues after this advertisement

Then, the patient takes three doses of the anti-depression nasal spray every five minutes under a doctor’s supervision. 

The patient remains in the clinic under observation until potential side effects have subsided. 

Side effects include hallucinations, feelings of being disconnected from reality, and headaches. 

If esketamine seems familiar, that’s probably because it’s a component of ketamine. It was once popular as a party drug called Special K.

Fortunately, Spravato underwent 31 clinical trials over the past six years and a phase 4 trial, which approved it for monotherapy use. 

“Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them,” said Johnson & Johnson neuroscientist Bill Martin.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

“For more than six years, I’ve seen firsthand the real-world impact Spravato can have on patients’ lives,” says psychiatrist Gregory Mattingly, who was part of the original clinical trials on the drug.

TOPICS: technology
TAGS: technology

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2025 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.